What changed from existing technology?
This study shows that blocking a protein called ATR can make Merkel cell carcinoma tumors more visible to the immune system, even if they lack another immune system pathway called cGAS-STING.
This study reveals that ATR inhibition can induce immunogenicity in Merkel cell carcinoma through a novel NF-κB-dependent mechanism, independent of the cGAS-STING pathway, which was previously thought to be essential for this process.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
. There is a major unmet need to develop therapies for patients whose tumors do not respond to PD-1 blockade. Inhibition of the ATR-mediated DNA replication c
Abstract ↗ntitumor immunity, although the underlying mechanisms remain poorly understood, particularly in cGAS-STING-deficient tumors. Here, we investigated the ef
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding suggests a potential therapeutic strategy for Merkel cell carcinoma patients who do not respond to PD-1 blockade, by targeting ATR to enhance antitumor immunity through an NF-κB-dependent pathway.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.